PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1933350
PUBLISHER: Fortune Business Insights Pvt. Ltd. | PRODUCT CODE: 1933350
Adults Vaccines Market Size, Share, Growth and Global Industry Analysis By Type & Application, Regional Insights and Forecast to 2026-2034
Growth Factors of adults vaccines Market
The global adults vaccines market is experiencing strong growth, supported by the rising burden of infectious diseases among adults, increasing geriatric population, and growing awareness regarding adult immunization. According to Fortune Business Insights, the global adults vaccines market was valued at USD 42.06 billion in 2025. The market is projected to grow from USD 45.22 billion in 2026 to USD 106.43 billion by 2034, registering a CAGR of 11.29% during the forecast period. In 2025, North America dominated the market with a share of 48.16%, driven by high vaccine uptake and advanced healthcare infrastructure.
Adult vaccination plays a critical role in protecting individuals and communities from serious and life-threatening diseases. As immune function declines with age, adults become more vulnerable to infections such as influenza, pneumonia, hepatitis, and shingles. The growing focus on preventive healthcare, along with strong government initiatives and technological advancements in vaccine platforms, continues to support market expansion.
Market Dynamics
Market Drivers
The increasing incidence of infectious diseases among adults is a major driver of market growth. Factors such as lifestyle changes, antimicrobial resistance, aging populations, and rising prevalence of chronic conditions have contributed to higher infection rates. This has significantly increased the demand for preventive vaccines. For instance, data published by the Centers for Disease Control and Prevention in August 2024 highlighted that influenza affects more than 8.8% of adults aged 18-64 annually in the U.S., underlining the growing need for adult vaccination programs.
Market Restraints
Vaccine hesitancy and misinformation remain key restraints for market growth. Misleading information shared through social media platforms has negatively impacted public trust in vaccines. Cultural and religious beliefs further influence vaccination decisions in certain regions. According to a medical journal published in November 2024, nearly 38.4% of adults expressed hesitancy toward COVID-19 vaccination, which may limit market expansion during the forecast period.
Market Opportunities
Technological advancements in vaccine development present significant growth opportunities. The adoption of mRNA platforms and novel formulations has improved vaccine efficacy and safety profiles. These advancements are expected to increase adult vaccination rates and reduce disease burden. In May 2025, Moderna announced that its mRNA platform could be applied to develop vaccines for infectious diseases, immuno-oncology, and autoimmune conditions, highlighting future growth potential.
Market Challenges
Lack of awareness regarding adult vaccination remains a critical challenge, particularly in emerging economies. Insufficient knowledge about vaccine benefits and safety often leads to delayed or missed immunizations. In February 2025, a survey conducted by GSK plc. revealed that over 56.6% of Indian participants aged 50 years and above were unaware of shingles disease, which may hinder vaccine adoption.
Adults Vaccines Market Trends
The development of combination vaccines has emerged as a prominent market trend. Combination vaccines reduce the number of injections required, improving convenience and compliance. Vaccines combining influenza, COVID-19, and RSV are expected to gain traction in the future. Additionally, governments worldwide are adopting life-course immunization strategies aligned with World Health Organization recommendations, supporting long-term market growth.
Segmentation Analysis
By type, the recombinant/conjugate/subunit segment dominated the market in 2024, driven by high efficacy and long-term immune protection. The inactivated vaccines segment also held a significant share due to its broad disease coverage and cost-effectiveness.
By route of administration, the parenteral segment led the market in 2024, supported by high bioavailability and rapid onset of action. The oral segment is expected to grow steadily due to ease of administration and improved safety.
By disease indication, the viral diseases segment dominated the market in 2024, driven by the high prevalence of influenza, hepatitis, and herpes zoster. The bacterial diseases segment also contributed notably due to rising concerns related to antimicrobial resistance.
By distribution channel, government suppliers dominated the market in 2024, supported by large-scale vaccination programs and global procurement initiatives.
Regional Outlook
North America led the market with a valuation of USD 19.45 billion in 2025 and USD 20.92 billion in 2026, supported by strong immunization infrastructure and favorable regulatory frameworks.
Europe held a significant share due to high government spending and active vaccine R&D initiatives.
Asia Pacific is the fastest-growing region, driven by high disease prevalence, expanding immunization programs, and increasing R&D activities.
Latin America and the Middle East & Africa are expected to grow steadily due to rising awareness and demand for advanced vaccines.
Competitive Landscape
The global adults vaccines market is concentrated, with GSK plc., Sanofi, and Serum Institute of India Pvt. Ltd. holding significant market shares. These companies benefit from strong vaccine portfolios, global distribution networks, and continuous product innovation. Other key players include Merck & Co., Inc., Pfizer Inc., AstraZeneca, Bavarian Nordic, and EMERGENT, which continue to invest heavily in research and development.
Conclusion
The global adults vaccines market is poised for robust growth throughout the forecast period, driven by the rising incidence of infectious diseases, expanding geriatric population, and increasing emphasis on preventive healthcare. With the market valued at USD 42.06 billion in 2025, projected to grow to USD 45.22 billion in 2026 and reach USD 106.43 billion by 2034, advancements in vaccine technology, growing government support, and strong industry pipelines are expected to shape the future of adult immunization. Despite challenges related to vaccine hesitancy and awareness gaps, sustained innovation and global immunization initiatives are anticipated to support long-term market expansion.
Segmentation By Type
- Recombinant/Conjugate/Subunit
- Inactivated
- mRNA
- Viral Vector
- Live Attenuated
- Toxoid
- Others
By Route of Administration
- Parenteral
- Oral
By Disease Indication
- Viral Diseases
- Hepatitis
- Influenza
- Human Papillomavirus
- Herpes Zoster
- Others
- Bacterial Diseases
- Meningococcal Disease
- Pneumococcal Disease
- Diphtheria/Tetanus/Pertussis
- Others
By Distribution Channel
- Hospital & Retail Pharmacies
- Government Suppliers
- Others
By Region
- North America (By Type, Route of Administration, Disease Indication, Distribution Channel, and Country)
- U.S.
- Canada
- Europe (By Type, Route of Administration, Disease Indication, Distribution Channel, and Country/Sub-region)
- Germany
- U.K.
- France
- Spain
- Italy
- Scandinavia
- Rest of Europe
- Asia Pacific (By Type, Route of Administration, Disease Indication, Distribution Channel, and Country/Sub-region)
- China
- Japan
- India
- Australia
- Southeast Asia
- Rest of Asia Pacific
- Latin America (By Type, Route of Administration, Disease Indication, Distribution Channel, and Country/Sub-region)
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa (By Type, Route of Administration, Disease Indication, Distribution Channel, and Country/Sub-region)
- GCC
- South Africa
- Rest of the Middle East & Africa
Table of Content
1. Introduction
- 1.1. Research Scope
- 1.2. Market Segmentation
- 1.3. Research Methodology
- 1.4. Definitions and Assumptions
2. Executive Summary
3. Market Dynamics
- 3.1. Market Drivers
- 3.2. Market Restraints
- 3.3. Market Opportunities
- 3.4. Market Trends
4. Key Insights
- 4.1. Incidence/Prevalence of Key Diseases, By Key Countries/Regions, 2025
- 4.2. Technological Advancements in the Adults Vaccines
- 4.3. New Product Launches, By Key Players
- 4.4. Pipeline Analysis, By Key Players
- 4.5. Key Industry Developments Such as Mergers, Acquisitions, and Partnerships
5. Global Adults Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 5.1. Market Analysis, Insights and Forecast - By Type
- 5.1.1. Recombinant/Conjugate/Subunit
- 5.1.2. Inactivated
- 5.1.3. mRNA
- 5.1.4. Viral Vector
- 5.1.5. Live Attenuated
- 5.1.6. Toxoid
- 5.1.7. Others
- 5.2. Market Analysis, Insights and Forecast - By Route of Administration
- 5.2.1. Parenteral
- 5.2.2. Oral
- 5.3. Market Analysis, Insights and Forecast - By Disease Indication
- 5.3.1. Viral Diseases
- 5.3.1.1. Hepatitis
- 5.3.1.2. Influenza
- 5.3.1.3. Human Papillomavirus
- 5.3.1.4. Herpes Zoster
- 5.3.1.5. Others
- 5.3.2. Bacterial Diseases
- 5.3.2.1. Meningococcal Disease
- 5.3.2.2. Pneumococcal Disease
- 5.3.2.3. Diphtheria/Tetanus/Pertussis
- 5.3.2.4. Others
- 5.3.1. Viral Diseases
- 5.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 5.4.1. Hospital & Retail Pharmacies
- 5.4.2. Government Suppliers
- 5.4.3. Others
- 5.5. Market Analysis, Insights and Forecast - By Region
- 5.5.1. North America
- 5.5.2. Europe
- 5.5.3. Asia Pacific
- 5.5.4. Latin America
- 5.5.5. Middle East & Africa
6. North America Adults Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 6.1. Market Analysis, Insights and Forecast - By Type
- 6.1.1. Recombinant/Conjugate/Subunit
- 6.1.2. Inactivated
- 6.1.3. mRNA
- 6.1.4. Viral Vector
- 6.1.5. Live Attenuated
- 6.1.6. Toxoid
- 6.1.7. Others
- 6.2. Market Analysis, Insights and Forecast - By Route of Administration
- 6.2.1. Parenteral
- 6.2.2. Oral
- 6.3. Market Analysis, Insights and Forecast - By Disease Indication
- 6.3.1. Viral Diseases
- 6.3.1.1. Hepatitis
- 6.3.1.2. Influenza
- 6.3.1.3. Human Papillomavirus
- 6.3.1.4. Herpes Zoster
- 6.3.1.5. Others
- 6.3.2. Bacterial Diseases
- 6.3.2.1. Meningococcal Disease
- 6.3.2.2. Pneumococcal Disease
- 6.3.2.3. Diphtheria/Tetanus/Pertussis
- 6.3.2.4. Others
- 6.3.1. Viral Diseases
- 6.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 6.4.1. Hospital & Retail Pharmacies
- 6.4.2. Government Suppliers
- 6.4.3. Others
- 6.5. Market Analysis, Insights and Forecast - By Country
- 6.5.1. U.S.
- 6.5.2. Canada
7. Europe Adults Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 7.1. Market Analysis, Insights and Forecast - By Type
- 7.1.1. Recombinant/Conjugate/Subunit
- 7.1.2. Inactivated
- 7.1.3. mRNA
- 7.1.4. Viral Vector
- 7.1.5. Live Attenuated
- 7.1.6. Toxoid
- 7.1.7. Others
- 7.2. Market Analysis, Insights and Forecast - By Route of Administration
- 7.2.1. Parenteral
- 7.2.2. Oral
- 7.3. Market Analysis, Insights and Forecast - By Disease Indication
- 7.3.1. Viral Diseases
- 7.3.1.1. Hepatitis
- 7.3.1.2. Influenza
- 7.3.1.3. Human Papillomavirus
- 7.3.1.4. Herpes Zoster
- 7.3.1.5. Others
- 7.3.2. Bacterial Diseases
- 7.3.2.1. Meningococcal Disease
- 7.3.2.2. Pneumococcal Disease
- 7.3.2.3. Diphtheria/Tetanus/Pertussis
- 7.3.2.4. Others
- 7.3.1. Viral Diseases
- 7.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 7.4.1. Hospital & Retail Pharmacies
- 7.4.2. Government Suppliers
- 7.4.3. Others
- 7.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 7.5.1. U.K.
- 7.5.2. Germany
- 7.5.3. France
- 7.5.4. Spain
- 7.5.5. Italy
- 7.5.6. Scandinavia
- 7.5.7. Rest of Europe
8. Asia Pacific Adults Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 8.1. Market Analysis, Insights and Forecast - By Type
- 8.1.1. Recombinant/Conjugate/Subunit
- 8.1.2. Inactivated
- 8.1.3. mRNA
- 8.1.4. Viral Vector
- 8.1.5. Live Attenuated
- 8.1.6. Toxoid
- 8.1.7. Others
- 8.2. Market Analysis, Insights and Forecast - By Route of Administration
- 8.2.1. Parenteral
- 8.2.2. Oral
- 8.3. Market Analysis, Insights and Forecast - By Disease Indication
- 8.3.1. Viral Diseases
- 8.3.1.1. Hepatitis
- 8.3.1.2. Influenza
- 8.3.1.3. Human Papillomavirus
- 8.3.1.4. Herpes Zoster
- 8.3.1.5. Others
- 8.3.2. Bacterial Diseases
- 8.3.2.1. Meningococcal Disease
- 8.3.2.2. Pneumococcal Disease
- 8.3.2.3. Diphtheria/Tetanus/Pertussis
- 8.3.2.4. Others
- 8.3.1. Viral Diseases
- 8.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 8.4.1. Hospital & Retail Pharmacies
- 8.4.2. Government Suppliers
- 8.4.3. Others
- 8.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 8.5.1. Japan
- 8.5.2. China
- 8.5.3. India
- 8.5.4. Australia
- 8.5.5. Southeast Asia
- 8.5.6. Rest of Asia Pacific
9. Latin America Adults Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 9.1. Market Analysis, Insights and Forecast - By Type
- 9.1.1. Recombinant/Conjugate/Subunit
- 9.1.2. Inactivated
- 9.1.3. mRNA
- 9.1.4. Viral Vector
- 9.1.5. Live Attenuated
- 9.1.6. Toxoid
- 9.1.7. Others
- 9.2. Market Analysis, Insights and Forecast - By Route of Administration
- 9.2.1. Parenteral
- 9.2.2. Oral
- 9.3. Market Analysis, Insights and Forecast - By Disease Indication
- 9.3.1. Viral Diseases
- 9.3.1.1. Hepatitis
- 9.3.1.2. Influenza
- 9.3.1.3. Human Papillomavirus
- 9.3.1.4. Herpes Zoster
- 9.3.1.5. Others
- 9.3.2. Bacterial Diseases
- 9.3.2.1. Meningococcal Disease
- 9.3.2.2. Pneumococcal Disease
- 9.3.2.3. Diphtheria/Tetanus/Pertussis
- 9.3.2.4. Others
- 9.3.1. Viral Diseases
- 9.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 9.4.1. Hospital & Retail Pharmacies
- 9.4.2. Government Suppliers
- 9.4.3. Others
- 9.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 9.5.1. Brazil
- 9.5.2. Mexico
- 9.5.3. Rest of Latin America
10. Middle East & Africa Adults Vaccines Market Analysis, Insights and Forecast, 2021-2034
- 10.1. Market Analysis, Insights and Forecast - By Type
- 10.1.1. Recombinant/Conjugate/Subunit
- 10.1.2. Inactivated
- 10.1.3. mRNA
- 10.1.4. Viral Vector
- 10.1.5. Live Attenuated
- 10.1.6. Toxoid
- 10.1.7. Others
- 10.2. Market Analysis, Insights and Forecast - By Route of Administration
- 10.2.1. Parenteral
- 10.2.2. Oral
- 10.3. Market Analysis, Insights and Forecast - By Disease Indication
- 10.3.1. Viral Diseases
- 10.3.1.1. Hepatitis
- 10.3.1.2. Influenza
- 10.3.1.3. Human Papillomavirus
- 10.3.1.4. Herpes Zoster
- 10.3.1.5. Others
- 10.3.2. Bacterial Diseases
- 10.3.2.1. Meningococcal Disease
- 10.3.2.2. Pneumococcal Disease
- 10.3.2.3. Diphtheria/Tetanus/Pertussis
- 10.3.2.4. Others
- 10.3.1. Viral Diseases
- 10.4. Market Analysis, Insights and Forecast - By Distribution Channel
- 10.4.1. Hospital & Retail Pharmacies
- 10.4.2. Government Suppliers
- 10.4.3. Others
- 10.5. Market Analysis, Insights and Forecast - By Country/Sub-region
- 10.5.1. GCC
- 10.5.2. South Africa
- 10.5.3. Rest of Middle East & Africa
11. Competitive Analysis
- 11.1. Global Market Share Analysis (2025)
- 11.2. Company Profiles
- 11.2.1. Bavarian Nordic
- 11.2.1.1. Overview
- 11.2.1.2. Products
- 11.2.1.3. SWOT Analysis
- 11.2.1.4. Recent Developments
- 11.2.1.5. Strategies
- 11.2.1.6. Financials (Based on Availability)
- 11.2.2. GSK plc
- 11.2.2.1. Overview
- 11.2.2.2. Products
- 11.2.2.3. SWOT Analysis
- 11.2.2.4. Recent Developments
- 11.2.2.5. Strategies
- 11.2.2.6. Financials (Based on Availability)
- 11.2.3. EMERGENT
- 11.2.3.1. Overview
- 11.2.3.2. Products
- 11.2.3.3. SWOT Analysis
- 11.2.3.4. Recent Developments
- 11.2.3.5. Strategies
- 11.2.3.6. Financials (Based on Availability)
- 11.2.4. Merck & Co., Inc.
- 11.2.4.1. Overview
- 11.2.4.2. Products
- 11.2.4.3. SWOT Analysis
- 11.2.4.4. Recent Developments
- 11.2.4.5. Strategies
- 11.2.4.6. Financials (Based on Availability)
- 11.2.5. Inovio Pharmaceuticals, Inc.
- 11.2.5.1. Overview
- 11.2.5.2. Products
- 11.2.5.3. SWOT Analysis
- 11.2.5.4. Recent Developments
- 11.2.5.5. Strategies
- 11.2.5.6. Financials (Based on Availability)
- 11.2.6. Pfizer Inc.
- 11.2.6.1. Overview
- 11.2.6.2. Products
- 11.2.6.3. SWOT Analysis
- 11.2.6.4. Recent Developments
- 11.2.6.5. Strategies
- 11.2.6.6. Financials (Based on Availability)
- 11.2.7. Sanofi
- 11.2.7.1. Overview
- 11.2.7.2. Products
- 11.2.7.3. SWOT Analysis
- 11.2.7.4. Recent Developments
- 11.2.7.5. Strategies
- 11.2.7.6. Financials (Based on Availability)
- 11.2.8. CSL
- 11.2.8.1. Overview
- 11.2.8.2. Products
- 11.2.8.3. SWOT Analysis
- 11.2.8.4. Recent Developments
- 11.2.8.5. Strategies
- 11.2.8.6. Financials (Based on Availability)
- 11.2.9. AstraZeneca
- 11.2.9.1. Overview
- 11.2.9.2. Products
- 11.2.9.3. SWOT Analysis
- 11.2.9.4. Recent Developments
- 11.2.9.5. Strategies
- 11.2.9.6. Financials (Based on Availability)
- 11.2.1. Bavarian Nordic
List of Tables
- Table 1: Global Adults Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 2: Global Adults Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 3: Global Adults Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
- Table 4: Global Adults Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034
- Table 5: Global Adults Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034
- Table 6: Global Adults Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 7: Global Adults Vaccines Market Revenue (USD billion) Forecast, by Region, 2021-2034
- Table 8: North America Adults Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 9: North America Adults Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 10: North America Adults Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
- Table 11: North America Adults Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034
- Table 12: North America Adults Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034
- Table 13: North America Adults Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 14: North America Adults Vaccines Market Revenue (USD billion) Forecast, By Country, 2021-2034
- Table 15: Europe Adults Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 16: Europe Adults Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 17: Europe Adults Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
- Table 18: Europe Adults Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034
- Table 19: Europe Adults Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034
- Table 20: Europe Adults Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 21: Europe Adults Vaccines Market Revenue (USD billion) Forecast, By Country/Sub-region, 2021-2034
- Table 22: Asia Pacific Adults Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 23: Asia Pacific Adults Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 24: Asia Pacific Adults Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
- Table 25: Asia Pacific Adults Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034
- Table 26: Asia Pacific Adults Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034
- Table 27: Asia Pacific Adults Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 28: Asia Pacific Adults Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 29: Latin America Adults Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 30: Latin America Adults Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 31: Latin America Adults Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
- Table 32: Latin America Adults Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034
- Table 33: Latin America Adults Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034
- Table 34: Latin America Adults Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 35: Latin America Adults Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
- Table 36: Middle East & Africa Adults Vaccines Market Revenue (USD billion) Forecast, by Type, 2021-2034
- Table 37: Middle East & Africa Adults Vaccines Market Revenue (USD billion) Forecast, by Route of Administration, 2021-2034
- Table 38: Middle East & Africa Adults Vaccines Market Revenue (USD billion) Forecast, by Disease Indication, 2021-2034
- Table 39: Middle East & Africa Adults Vaccines Market Revenue (USD billion) Forecast, by Viral Diseases, 2021-2034
- Table 40: Middle East & Africa Adults Vaccines Market Revenue (USD billion) Forecast, by Bacterial Diseases, 2021-2034
- Table 41: Middle East & Africa Adults Vaccines Market Revenue (USD billion) Forecast, by Distribution Channel, 2021-2034
- Table 42: Middle East & Africa Adults Vaccines Market Revenue (USD billion) Forecast, By Country/ Sub-region, 2021-2034
List of Figures
- Figure 1: Global Adults Vaccines Market Revenue Breakdown (USD billion, %) by Region, 2025 & 2034
- Figure 2: Global Adults Vaccines Market Value Share (%), by Type, 2025 & 2034
- Figure 3: Global Adults Vaccines Market Value Share (%), by Route of Administration, 2025 & 2034
- Figure 4: Global Adults Vaccines Market Value Share (%), by Disease Indication, 2025 & 2034
- Figure 5: Global Adults Vaccines Market Value Share (%), by Distribution Channel, 2025 & 2034
- Figure 6: Global Adults Vaccines Market Value Share (%), by Region, 2025 & 2034
- Figure 7: North America Adults Vaccines Market Value (USD billion), by Type, 2025 & 2034
- Figure 8: North America Adults Vaccines Market Value Share (%), by Type, 2025
- Figure 9: North America Adults Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 10: North America Adults Vaccines Market Value Share (%), by Route of Administration, 2025
- Figure 11: North America Adults Vaccines Market Value (USD billion), by Disease Indication, 2025 & 2034
- Figure 12: North America Adults Vaccines Market Value Share (%), by Disease Indication, 2025
- Figure 13: North America Adults Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 14: North America Adults Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 15: North America Adults Vaccines Market Value (USD billion), By Country, 2025 & 2034
- Figure 16: North America Adults Vaccines Market Value Share (%), By Country, 2025
- Figure 17: Europe Adults Vaccines Market Value (USD billion), by Type, 2025 & 2034
- Figure 18: Europe Adults Vaccines Market Value Share (%), by Type, 2025
- Figure 19: Europe Adults Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 20: Europe Adults Vaccines Market Value Share (%), by Route of Administration, 2025
- Figure 21: Europe Adults Vaccines Market Value (USD billion), by Disease Indication, 2025 & 2034
- Figure 22: Europe Adults Vaccines Market Value Share (%), by Disease Indication, 2025
- Figure 23: Europe Adults Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 24: Europe Adults Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 25: Europe Adults Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 26: Europe Adults Vaccines Market Value Share (%), By Country/ Sub-region, 2025
- Figure 27: Asia Pacific Adults Vaccines Market Value (USD billion), by Type, 2025 & 2034
- Figure 28: Asia Pacific Adults Vaccines Market Value Share (%), by Type, 2025
- Figure 29: Asia Pacific Adults Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 30: Asia Pacific Adults Vaccines Market Value Share (%), by Route of Administration, 2025
- Figure 31: Asia Pacific Adults Vaccines Market Value (USD billion), by Disease Indication, 2025 & 2034
- Figure 32: Asia Pacific Adults Vaccines Market Value Share (%), by Disease Indication, 2025
- Figure 33: Asia Pacific Adults Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 34: Asia Pacific Adults Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 35: Asia Pacific Adults Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 36: Asia Pacific Adults Vaccines Market Value Share (%), By Country/ Sub-region, 2025
- Figure 37: Latin America Adults Vaccines Market Value (USD billion), by Type, 2025 & 2034
- Figure 38: Latin America Adults Vaccines Market Value Share (%), by Type, 2025
- Figure 39: Latin America Adults Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 40: Latin America Adults Vaccines Market Value Share (%), by Route of Administration, 2025
- Figure 41: Latin America Adults Vaccines Market Value (USD billion), by Disease Indication, 2025 & 2034
- Figure 42: Latin America Adults Vaccines Market Value Share (%), by Disease Indication, 2025
- Figure 43: Latin America Adults Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 44: Latin America Adults Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 45: Latin America Adults Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 46: Latin America Adults Vaccines Market Value Share (%), By Country/ Sub-region, 2025
- Figure 47: Middle East & Africa Adults Vaccines Market Value (USD billion), by Type, 2025 & 2034
- Figure 48: Middle East & Africa Adults Vaccines Market Value Share (%), by Type, 2025
- Figure 49: Middle East & Africa Adults Vaccines Market Value (USD billion), by Route of Administration, 2025 & 2034
- Figure 50: Middle East & Africa Adults Vaccines Market Value Share (%), by Route of Administration, 2025
- Figure 51: Middle East & Africa Adults Vaccines Market Value (USD billion), by Disease Indication, 2025 & 2034
- Figure 52: Middle East & Africa Adults Vaccines Market Value Share (%), by Disease Indication, 2025
- Figure 53: Middle East & Africa Adults Vaccines Market Value (USD billion), by Distribution Channel, 2025 & 2034
- Figure 54: Middle East & Africa Adults Vaccines Market Value Share (%), by Distribution Channel, 2025
- Figure 55: Middle East & Africa Adults Vaccines Market Value (USD billion), By Country/ Sub-region, 2025 & 2034
- Figure 56: Middle East & Africa Adults Vaccines Market Value Share (%), By Country/ Sub-region, 2025
- Figure 57: Global Adults Vaccines Market Share (%), By Company, 2025
